Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
VitD3 Supplementation in Patients With Multiple Myeloma
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC
- Status
- UNKNOWN
- Phase
- PHASE2
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
- Status
- WITHDRAWN
- Phase
- PHASE2
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients
- Status
- UNKNOWN
- Phase
- PHASE3
GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Status
- UNKNOWN
- Phase
- NA
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
- Status
- RECRUITING
- Phase
- PHASE2
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
- Status
- RECRUITING
- Phase
- PHASE2
Elimination of Minimal Residual Disease After Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Chidamide in Patients With Recurrent and Refractory Diffuse Large b
- Status
- ENROLLING_BY_INVITATION
- Phase
- N/A
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE2
Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2